Insmed, Inc. (INSM)
114.40
+5.64
(+5.19%)
USD |
NASDAQ |
Nov 06, 16:00
114.48
+0.08
(+0.07%)
After-Hours: 20:00
Insmed Net Income (TTM) : -605.61M for Sept. 30, 2026
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | -605.61M |
| June 30, 2026 | -875.31M |
| March 31, 2026 | -1.184B |
| December 31, 2025 | -1.277B |
| September 30, 2025 | -1.184B |
| June 30, 2025 | -1.034B |
| March 31, 2025 | -1.013B |
| December 31, 2024 | -913.77M |
| September 30, 2024 | -864.28M |
| June 30, 2024 | -802.69M |
| March 31, 2024 | -746.89M |
| December 31, 2023 | -749.57M |
| September 30, 2023 | -723.63M |
| June 30, 2023 | -695.84M |
| March 31, 2023 | -546.68M |
| December 31, 2022 | -481.53M |
| September 30, 2022 | -434.39M |
| June 30, 2022 | -415.96M |
| March 31, 2022 | -437.63M |
| December 31, 2021 | -434.65M |
| September 30, 2021 | -423.89M |
| June 30, 2021 | -374.83M |
| March 31, 2021 | -319.37M |
| December 31, 2020 | -294.09M |
| September 30, 2020 | -244.86M |
| Date | Value |
|---|---|
| June 30, 2020 | -241.89M |
| March 31, 2020 | -246.55M |
| December 31, 2019 | -254.34M |
| September 30, 2019 | -292.92M |
| June 30, 2019 | -319.98M |
| March 31, 2019 | -329.91M |
| December 31, 2018 | -324.28M |
| September 30, 2018 | -298.09M |
| June 30, 2018 | -255.52M |
| March 31, 2018 | -223.76M |
| December 31, 2017 | -192.65M |
| September 30, 2017 | -195.67M |
| June 30, 2017 | -188.25M |
| March 31, 2017 | -180.16M |
| December 31, 2016 | -176.27M |
| September 30, 2016 | -139.12M |
| June 30, 2016 | -132.32M |
| March 31, 2016 | -124.35M |
| December 31, 2015 | -118.18M |
| September 30, 2015 | -104.58M |
| June 30, 2015 | -97.61M |
| March 31, 2015 | -92.23M |
| December 31, 2014 | -79.16M |
| September 30, 2014 | -77.73M |
| June 30, 2014 | -71.06M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 2.724B |
| Gilead Sciences, Inc. | -3.863B |
| Incyte Corp. | 403.41M |
| Vertex Pharmaceuticals, Inc. | 3.976B |
| Regeneron Pharmaceuticals, Inc. | 4.817B |